Results 231 to 240 of about 268,296 (309)

Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review. [PDF]

Cureus
Pereira F, Pimenta JL, Rei M, Dias CR, Pereira D.   +4 more
europepmc   +1 more source

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms

British Journal of Pharmacology, EarlyView.
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl, Jakub Morze, Sabina Wallerer, Georg Hoffmann   +3 more
wiley   +1 more source

Identification and functional evaluation of cyclin-dependent kinase genes reveals that CDKB1;1 and CDKB2;2 contribute to the balance of mitosis and endoreduplication in Medicago truncatula nodule. [PDF]

BMC Plant Biol
Wang R, Pan H.
europepmc   +1 more source

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

British Journal of Pharmacology, EarlyView.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, Robert Fredriksson, Francisco Lagunas‐Rangel, Alexander S. Hauser, Stefan Knapp, Jörgen Jonsson, Helgi B. Schiöth   +8 more
wiley   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future. [PDF]

Cancers (Basel)
Siskin M, Economides MP, Wise DR.
europepmc   +1 more source

O‐GlcNAcylation of KAT2A Enhances Bladder Cancer Proliferation by Inhibiting the KAT2A‐TRIM22 Interaction

Cancer Science, EarlyView.
Lysine acetyltransferase 2A (KAT2A) is a transcriptional coactivator and a member of the Histone Acetyltransferase (HAT) family. While altered KAT2A activity has been implicated in various cancers, its role in bladder cancer (BLCA) remains poorly understood.
Wenjie Yang, Zhaoheng Jin, Ziyi Li, Weifeng Xu, Yingjie Li, Yueqiang Peng, Jie Dong, Lin Ma, Zhigang Ji   +8 more
wiley   +1 more source

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors <i>in silico</i>. [PDF]

Biochem Biophys Rep
Asamitsu K, Hirokawa T, Okamoto T.
europepmc   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

Cancer Science, EarlyView.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah, Mackenzie M. Mayhew, Jacob Sellers, Russell G. Witt   +3 more
wiley   +1 more source

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study. [PDF]

Breast
Pontolillo L, Munzone E, Vigneri P, Pistelli M, Palazzo A, La Verde N, Mazzotta M, Paris I, Alesini D, Santini D, Cannita K, Orlandi A, Magnolfi E, Giacinti L, Raffaele M, Carbognin L, Santoro A, Rossi A, Arcuri G, Sangalli C, Garrone O, Mulè A, Valenza C, Berardi R, Tortora G, Bria E, Curigliano G, Giannarelli D, Fabi A.   +28 more
europepmc   +1 more source